The ability of Ras oncoproteins to cause malignant transformation requires their post-translational modi®ca-tions by prenyl groups. Because K-Ras can be both farnesylated and geranylgeranylated it is not known whether both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for suppressing human tumor growth in whole animals. In this paper we report that oncogenic Ras processing, MAP kinase activation and growth in nude mice are inhibited by the farnesyltransferase inhibitor FTI-276 in H-and N-Ras transformed NIH3T3 cells; whereas in K B -Ras transformed NIH3T3 cells both FTI-276 and the geranylgeranyltransferase I inhibitor GGTI-297 are required for inhibition. Furthermore, human lung A-549 and Calu-1 carcinoma cell lines were found to co-express H-, N-and K-Ras. In Calu-1 cells, the processing of H-and N-Ras is inhibited greatly by FTI-276 but only partially by GGTI-297 whereas K-Ras processing inhibition requires both FTI-276 and GGTI-297. In contrast, in A-549 cells the processing of H-and N-Ras is inhibited only by FTI-276 and K-Ras processing is resistant to co-treatment with FTI-276 and GGTI-297. Yet, the growth in nude mice of A-549 and Calu-1 xenografts, both of which express K-Ras mutations, is inhibited by FTI-276 (80% inhibition) and GGTI-297 (60%). Furthermore, FTI-276 inhibits tumor growth of NIH3T3 cells transformed by a form of oncogenic H-Ras that is exclusively geranylgeranylated and whose processing is resistant to this inhibitor. Taken together, the results demonstrate that both FTase and GGTase I inhibitors are required for inhibition of K-Ras processing but that each alone is sucient to suppress human tumor growth in nude mice.
Introduction
Ras proteins are GTPases that regulate proliferation and dierentiation by transducing biological information from extracellular signals to the nucleus (McCormick et al., 1993 (McCormick et al., , 1994 . Mutations that lock Ras proteins in their GTP-bound, activated state result in uncontrolled growth and malignant transformation (Barbacid, 1987) . Thirty percent of all human cancers express oncogenically activated Ras with predominance in pancreatic (90%), colorectal (50%) and lung (20%) cancer patients (Bos, 1989) . Although, mammalian cells express three ras genes that encode four Ras proteins (H-, N-, K A -and K B -Ras), the most prevalent activated Ras in human cancers is of the K-type (Bos, 1989) . Disruption of activated K-Ras function alone is sucient for reversion to normal of the malignant phenotype of human tumors with multiple genetic alterations. For example, elimination of oncogenic ras function by homologous gene recombination of the mutated ras allele resulted in inhibition of tumor growth in nude mice of the human colorectal carcinoma cells line DLD1 which contains several genetic alterations including mutations in K-Ras and the tumor suppressor gene p53 (Shirasawa et al., 1993) . Thus, pharmacological agents that can block oncogenic Ras activity have great therapeutic potential as anticancer drugs.
One approach that has recently been taken is to design inhibitors of farnesyltransferase (FTase), an enzyme responsible for a key posttranslational step during the processing of Ras. These inhibitors block the functionalization of Ras by the lipid C 15 farnesyl, a posttranslational modi®cation required for Ras membrane association and cancer-causing activity (for reviews see Sebti and Hamilton, 1997; Satler and Tamanoi, 1996; Buss and Marsters, 1995; Gibbs et al., 1994) . All Ras proteins contain a carboxyl terminal tetrapeptide CAAX (C=Cys, A=Val or Ile, X=Ser or Met) that is required for initiation of post-translational processing. FTase attaches a farnesyl group to the cysteine sulfhydryl of the CAAX box. Farnesylation is followed by peptidase removal of the`AAX' tripeptide and methylation of the resulting cysteine carboxylate. Because farnesylation is sucient and required for membrane anchoring of Ras and malignant transformation (Kato et al., 1992) , FTase has become one of the most sought-after targets for developing novel anticancer drugs Satler and Tamanoi, 1996; Buss and Marsters, 1995; Gibbs et al., 1994) . Over the last 5 years we Nigam et al., 1993; Qian et al., 1994a, b; Vogt et al., 1995) and others (Kohl et al., 1993; James et al., 1993; Graham et al., 1994; Patel et al., 1995; Bishop et al., 1995; Garcia et al., 1993) have used the CAAX tetrapeptide to design peptidomimetics that are highly selective and potent inhibitors of FTase. These inhibitors disrupted oncogenic H-Ras but not Raf signaling and inhibited tumor growth in nude mice of NIH3T3 cells transformed by H-ras but not those transformed by Raf oncogenes (Sun et al., l995; Kohl et al., 1995; Nagasu et al., 1995) . Furthermore, CAAX peptidomimetics inhibited the anchorage-dependent growth of ras-transformed cells but had little eect on the growth of normal cells (Kohl et al., 1993; James et al., 1993) . However, the ability of FTase inhibitors to reverse morphological transformation was shown not to correlate with their ability to inhibit Ras prenylation (Prendergast et al., 1994) , and the Ras mutation status did not predict the sensitivity of human tumor cell growth in soft agar (SeppLorenzino et al., 1995) .
One drawback of the studies using ras oncogenetransformed cells to investigate the mechanism of action of FTase inhibitors is that H-Ras was used and it was soon discovered that the most prevalent K-Ras was resistant to FTase inhibitors Lerner et al., 1995a) . For example, the CAAX peptidomimetic FTI-277 inhibited H-Ras processing and oncogenic signaling with an IC 50 of 0.1 mM whereas inhibition of K B -Ras function required 100-fold higher concentrations . We have subsequently designed an inhibitor to the closely related enzyme geranylgeranyltransferase I (GGTase I), which transfers a C 20 geranylgeranyl group to the cysteine of CAAX sequences that have a leucine at the carboxyl terminus, and shown that K B -Ras processing and oncogenic signaling was sensitive to this inhibitor (Lerner et al., 1995b) . This was consistent with the work of which showed that K B -Ras can be both farnesylated and geranylgeranylated in vitro as well as with the more recent work of Whyte et al. (1997) and Rowell et al. (1997) in intact human tumor cell lines. The above studies, however, were carried out in cells transfected with an exogenous K B -Ras oncogene and whether or not inhibition of the processing of K-Ras in human tumors requires both FTase and GGTase I inhibitors has not been investigated. Furthermore, the antitumor activity, against human tumor xenografts as well as oncogene-transformed NIH3T3 cells, of GGTase I inhibitors alone or in combination with FTase inhibitors has not been determined. In the present study we have used an FTase (FTI-276) and a GGTase I (GGTI-297) Vogt et al., 1996) speci®c inhibitor alone or in combination to investigate the processing, oncogenic signaling and tumor growth in nude mice of H-, N-and K B -Ras transformed NIH3T3 cells as well as human tumor cell lines with K-Ras mutations.
Results

Eects of prenyltransferase inhibitors on oncogenic Ras processing and signaling in NIH3T3 transformed cells
Recently, we have designed low molecular weight compounds, that mimic the carboxyl terminal CAAX of Ras and other small G proteins as potent and selective inhibitors of prenyltransferases. For example, FTI-276 is a peptidomimetic of the C-terminal tetrapeptides of K B -Ras (CVIM), K A -Ras (CIIM) and N-Ras (CVVM) where reduced cysteine was coupled to methionine by 2-phenyl-4-aminobenzoic acid (Lerner et al., 1995a) . GGTI-297 is a peptidomimetic where reduced cysteine was linked to leucine by 2-naphthyl-4-aminobenzoic acid Vogt et al., 1996) . FTI-276 is highly selective for FTase over GGTase I in vitro and its methyl ester FTI-277 inhibits selectively H-Ras processing without aecting the processing of the geranylgeranylated protein RaplA . GGTI-297 and its methyl ester GGT1-298, on the other hand, are selective for GGTase I over FTase and inhibit Rap1A processing at concentrations that do not aect H-Ras processing Vogt et al., 1996) . In this paper we investigated the eects of FTI-277 and GGTI-298 alone or in combination on the processing, oncogenic signaling and tumor growth in nude mice of H-, Nand K B -Ras transformed NIH3T3 cells as well as human tumors. NIH3T3 cells transformed by oncogenic H-, K B -or N-Ras were treated with either FTI-277 or GGTI-298, alone or in combination and the cell lysates were electrophoresed and immunoblotted either with anti-Ras or anti-MAPK (erk-2) antibodies as described under Materials and methods. Figure 1a shows that cells treated with vehicle expressed only fully processed Ras. FTI-277 blocked H-Ras and NRas processing and had no eect on K B -Ras processing. In contrast, GGTI-298 had no eect on H-Ras and N-Ras processing but, concentrations as low as 5 mM of this inhibitor partially inhibited and 20 mM had a more pronounced eect on K B -Ras processing ( Figure 1a ). Co-treatment with FTI-277 (5 mM) and GGTI-298 (5 mM) had a synergistic eect and combination with GGTI-298 (20 mM) resulted in a complete block of K B -Ras processing ( Figure 1a ). These data suggest that both H-and N-Ras are exclusively farnesylated and are resistant to inhibition by GGTase I inhibitors. On the other hand, the data suggest that K B -Ras in NIH3T3 cells transfected by this oncogene can be both farnesylated and geranylgeranylated and that both FTase and GGTase I inhibitors are required for complete inhibition of the processing of this form of Ras. We have also determined the eects of FTI-277 and GGTI-298 on the processing of a form of H-Ras that has a mutated CVLL instead of the wild type CVLS carboxyl terminal sequence . In contrast to H-Ras CVLS, the processing of H-Ras CVLL was inhibited, as expected, by GGTI-298 but not FTI-277 ( Figure 1a) .
We next investigated the eects of these inhibitors on constitutive activation of MAP kinase by the various Ras proteins. , the animals were injected i.p. daily with 70 mg/kg of either FTI-276 or GGTI-297 or a combination of FTI-276 (35 mg/kg) and GGTI-297 (35 mg/kg). The eects of these drug treatments on tumor growth was determined as described in the legend to Table 1 and under Materials and methods. Table 1 shows that treatment with FTI-276 alone inhibited tumor growth of N-Ras and H-Ras CVLS transformed cells by an average of 65% and 59%, respectively, but only 27% that of K B -Ras CVIM transformed cells. GGTI-297, on the other hand, inhibited tumor growth of all three cell lines by about 40%. Thus, H-Ras CVLS or N-Ras transformed cells were more sensitive to FTI-276 than were K B -Ras transformed cells, whereas all three cell lines were equisensitive to GGTI-297. Co-treatment of mice bearing H-, K B -and N-Ras transformed tumors with the FTI-276 and GGTI-297 combination resulted in an average tumor growth inhibition of 64, 65 and 57%, respectively (Table 1) . Thus, co-treatment with GGTI-297/FTI-276 had an additive inhibitory eect only on the growth of K B -Ras but not H-Ras CVLS or N-Ras transformed cells.
Although the data in Figure 1 and Table 1 show a good correlation between the ability of the prenyltransferase inhibitors to disrupt oncogenic Ras processing and signaling and their inhibition of tumor growth, a more direct approach to determine whether inhibition of prenylation is required for antitumor activity in vivo is to use NIH3T3 cells transformed with H-Ras CVLL that is only geranylgeranylated . Treatment of animals bearing NIH3T3 cells that express oncogenic H-Ras CVLL with FTI-276 (70 mg/kg) inhibited tumor growth by 51% (Table 1) . GGTI-297 (70 mg/kg) also inhibited tumor growth by 51% (Table 1 ). The combination of FTI-276 (35 mg/ kg) and GGTI-297 (35 mg/kg) had a slightly higher eect (60% inhibition) ( Table 1 ). These results demonstrated that FTI-276 inhibited tumor growth of geranylgeranylated H-Ras CVLL and farnesylated HRas CVLS transformed cells to the same extent.
Eects of FTI-276 and GGTI-297 on H, K and N-Ras processing and growth of human tumor cell lines in nude mice xenografts
The above data with H-Ras CVLL transformed NIH3T3 cells suggested that inhibition of Ras processing is not necessary for suppression of tumor growth in nude mice. The next question we addressed was whether this is also the case in human tumor cell lines with naturally occurring K-Ras mutations. We ®rst investigated the eects of FTI-277 and GGTI-298 on Ras processing in the human lung carcinoma cell lines A-549 and Calu-1. The tumor cells were treated with FTI-277 or GGTI-298 alone or in combination and the lysates were immunoblotted with anti-H-Ras, anti-N-Ras, anti-K-Ras or anti-K B -Ras speci®c antibodies. In Calu-1 cells the prenylation of N-Ras and H-Ras was sensitive to FTI-277 but that of K-Ras was resistant (Figure 2) . Furthermore, GGTI-298 partially inhibited the prenylation of both H-Ras and N-Ras but did not aect that of K-Ras. Thus, the prenylation of K-Ras from Calu-1 cells is highly resistant to FTI-277 and GGTI-298. However, co-treatment of Calu-1 cells with high concentrations of FTI-277 (50 mM) and GGTI-298 (15 mM) resulted in a substantial inhibition of K-Ras prenylation (Figure 2 ). In A-549 cells. H-Ras and N-Ras prenylation were sensitive to FTI-277 but resistant to GGTI-298 ( Figure 2 ). K-Ras prenylation was highly resistant even when A-549 cells were cotreated with FTI-277 (50 mM) and GGTI-298 (15 mM) (Figure 2 ). The fact that in Calu-1 cells, treatment with both FTase and GGTase I inhibitors is required for inhibition of K-Ras processing suggests that the resistance of K-Ras prenylation to FTase inhibitors is due to alternative prenylation by GGTase I. In A-549 cells, however, K-Ras prenylation was highly resistant to the co-treatment with FTase and GGTase I inhibitors. The resistance to FTI-277 and GGTI-298 and the response of Calu-1 but not A-549 cells to the co-treatment was also con®rmed by using antibodies speci®c for K B -Ras (Figure 2) . No detectable levels of K A -Ras were found in these two human tumor cell lines (data not shown). The ability of FTI-276 and GGTI-297 to inhibit tumor growth of A-549 and Calu-1 cells was next investigated. Nude mice were implanted s.c. with the tumor cells and when the tumors reached 50 to 100 mm 3 , the animals were injected daily i.p. with 70 mg/kg of either FTI-276 or GGTI-297 or a combination of FTI-276 (35 mg/kg) and GGTI-297 (35 mg/kg). Figure 3 shows that in the absence of inhibitors, A-549 and Calu-1 tumors grew to about 700 and 500 mm 3 over a period of about 5 and 12 weeks, respectively. Daily injections of the inhibitors indicated that FTI-276 was a more eective antitumor agent than GGTI ± 297 (Figure 3) . Table 2 shows percentage inhibition of tumor growth of A-549 and Calu-1 cells from three independent experiments. On average, treatment with FTI-276 resulted in 80% inhibition of tumor growth compared to 60% with GGTI-297. Cotreatment with FTI-276 and GGTI-297 did not increase the antitumor ecacy above that seen with FTI-276 alone (Table 2 ). These treatments did not result in any weight loss of the animals. Thus, FTI-276 and GGTI-297 were able to inhibit eciently the growth of A-549 and Calu-1 cells even though they were ineective at inhibiting prenylation of their mutated K-Ras. 
Discussion
A potential mechanism by which K B -Ras prenylation resists FTase inhibitors is geranylgeranylation by GGTase I . We have therefore made GGTase I inhibitors and used these compounds to give further support for this notion (Lerner et al., 1995b and Figure 1 ). More recently, K-and N-Ras have been shown to be geranylgeranylated in cells treated with FTase inhibitors (Whyte et al., 1997; Rowell et al., 1997) . Although the eects of FTase inhibitors on normal and malignant cells have been well studied, only recently have the eects of GGTase I inhibitors been investigated. For example, GGTI-298, but not FTI-277, blocks PDGF-and EGF-dependent tyrosine phosphorylation of their respective receptors . Treatment of cells with GGTI-298 also induces a G0/Gl-phase arrest and apoptosis Miquel et al., 1997) . In addition to their eects on ®broblasts (Rat-l and NIH3T3 cells) Vogt et al., 1996) and human tumor cells of epithelial origin (Miquel et al., 1997) , GGTase I inhibitors also enhance the ability of IL±1b to induce nitric oxide synthase-2 in smooth muscle cells (Finder et al., 1997) . Furthermore, GGTI-298 treatment of cells results in an induction of the cyclindependent kinase inhibitor p21 WAF but not p27 Kip (Vogt et al., 1997) . Although in cultured cells GGTase I inhibitors can induce a G0/Gl-phase arrest and apoptosis it is not known whether they can suppress murine and human tumor growth in whole animals. In the present study we have demonstrated that the GGTase I inhibitor GGTI-297 was able to inhibit the growth of ras oncogene-transformed NIH3T3 cells in nude mice by about 40%. Furthermore GGTI-297 was more ecacious (60%) at inhibiting the in vivo growth of human tumors. The fact that GGTase I inhibitors also have antitumor activity suggests that some substrates for GGTase I are important for malignant transformation. This is consistent with reports that demonstrated that two geranylgeranylated proteins (RhoA and Rac l) are transforming in their GTPlocked form (Khosravi-Far et al., 1995; Qiu et al., 1995) . Furthermore, RhoA and Rac 1 were shown to act downstream of Ras and their dominant negative forms were able to revert partially Ras transformation (Khosravi-Far et al., 1995; Qiu et al., 1995) . This is also consistent with our results that show only partial inhibition of the growth of ras oncogene-transformed NIH3T3 cells and human tumors by GGTI-297.
In this manuscript we also demonstrate that both A-549 and Calu-1 human lung carcinoma cell lines express H-, K-and N-Ras proteins and that their sensitivities to FTI-277 and GGTI-297 vary greatly. While the prenylation of H-Ras and N-Ras is more sensitive to FTI-277 than GGTI-298, the prenylation of K-Ras is resistant to both inhibitors. The same results obtained with K-Ras were also observed when antibodies speci®c for K B -Ras were used (Figure 2) , and both A-549 and Calu-1 cells had no detectable levels of K A -Ras (data not shown). In Calu-1 cells, cotreatment with FTI-277 and GGTI-298 was necessary to inhibit K B -Ras prenylation suggesting that K B -Ras can be geranylgeranylated and farnesylated. This is consistent with previous reports from our and other laboratories (Lerner et al., 1995b; James et al., 1995; Figure 3 Antitumor ecacy of FTI-276 and GGTI-297 against A-549 and Calu-1 human lung carcinoma xenografts. A-549 (A) and Calu-1 (B) cells were injected s.c. at day 0 into the right and left¯anks (7.0610 6 cells/¯ank) of 8-week-old female nude mice. When the tumor size reached an average of 50 ± 120 mm 3 , control animals were treated i.p. daily with saline (0), GGTI-297 (70 mg/ kg) (~) or FTI-276 (70 mg/kg) (!) as described in Materials and methods. Data are representative of three independent experiments. Each data point is an average of eight tumors. Statistical signi®cance between control and treated groups were evaluated by using Student's t-test (P50.05) FTI-276 and GGTI-297 antitumor activity and K-Ras prenylation J Sun et al Whyte et al., 1997; Rowell et al., 1997) . In A-549 cells, co-treatment with FTI-277 and GGTI-298 did not inhibit K B -Ras prenylation. Both inhibitors were able to reach their targets in A-549 cells since FTI-277 inhibited H-and N-Ras processing ( Figure 2 ) and GGTI-298 inhibited Rap lA processing in A-549 cells (Miquel et al., 1997) . Thus the results suggest either that K B -Ras from A-549 cells has an extremely high anity for FTase and/or GGTase I or that it is processed by a dierent enzyme. Although FTI-276 was unable to inhibit K-Ras prenylation, it was very ecacious at suppressing tumor growth of both A-549 and Calu-1 cells in the nude mouse xenograft model. Furthermore, FTI-277 (50 mM) inhibited by 70% and 90% the anchorageindependent growth in soft agar of A-549 and Calu-1 cells, respectively (Lerner et al., 1997) . Thus, in two models of transformation (nude mouse xenografts and soft agar), inhibition of growth did not require inhibition of oncogenic K-Ras processing. This tumor growth inhibition is not due to non-speci®c growth inhibition of FTase inhibitors since we have previously shown that FTI-276 inhibits the growth in nude mice of H-Ras-but not Raf-transformed NIH3T3 cells . Consistent with this, is work by others showing the speci®city and lack of toxicity of FTase inhibitors in whole animals Nagasu et al., 1995) . Furthermore, our soft agar results are consistent with those of Sepp-Lorenzino et al. (1995) who showed that the ability of FTase inhibitors to inhibit human tumor cell line growth in soft agar does not correlate with their Ras mutation status. In addition, others have demonstrated that the ability of FTase inhibitors to reverse morphological transformation did not correlate with their ability to inhibit Ras prenylation (Prendergast et al., 1994) . Taken together these results suggest that farnesylated protein(s) other than oncogenic K-Ras, that are pivotal to transformation, are targets for FTase inhibitors. Although the antitumor ecacy of FTI-276 correlates well with its ability to disrupt H-Ras CVLS, N-Ras and K B -Ras prenylation in NIH3T3 cells, FTI-276 inhibited tumor growth of NIH3T3 cells transformed by H-Ras CVLL without aecting its prenylation. This is not consistent with previous studies that showed that the growth of these cells in soft agar was minimally aected by another FTase inhibitor, B581 (Cox et al., 1994) . This could either be due to dierences between soft agar and whole animals or dierent properties of the two classes of FTase inhibitors. Nevertheless, the fact that FTI-276 inhibited the growth in vivo of H-Ras CVLLtransformed NIH3T3 cells gives further support to the suggestion that FTase inhibitors have other targets besides Ras. Based on the high antitumor ecacy observed with FTI-276 these farnesylated proteins are predicted to have a lower anity for FTase than KRas. Possible candidates are RhoB, H-Ras, N-Ras, or lamin B, the prenylation of which we have shown to be blocked by concentrations of FTI-277 as low as 5 mM in A-549 (Miquel et al., 1997) . RhoB has been suggested as a target for FTase inhibitors based on the fact that Rat-1 cells transformed with oncogenic ras become resistant to FTase inhibitors when transfected with a RhoB mutant that is myristylated and not farnesylated and/or geranylgeranylated (Lebowitz et al., 1995) . More recent work from the same group demonstrated that RhoB is a substrate for FTase, and that FTase inhibitors block RhoB farnesylation and resulted in an increased proportion of geranylgeranylated RhoB in whole cells (Lebowitz et al., 1997) . The observation that RhoB is farnesylated by FTase is inconsistent with previous work that showed that RhoB is both farnesylated and geranylgeranylated by GGTase I (Armstrong et al., 1995) . Although the work of Lebowitz et al. (1995 and suggests that RhoB is a target for FTase inhibitors' antitumor activity, further studies are required to strengthen this hypothesis. Alternatively, a yet unknown protein that plays a key role in transformation and that requires farnesylation for function could be the target for FTase inhibitors.
Antitumor activity in the nude mouse tumor xenograft model Nude mice (Harlan Sprague Dawley, Indianapolis, Indiana or Charles River, Wilmington, Massachusetts) were maintained in accordance with the Institutional Animal Care and Use Committee (IACUC) procedures and guidelines. A-549 and Calu-1 cells were harvested, resuspended in PBS and injected s.c. into the right and left¯ank (7610 6 cells per¯ank) of 8 week old female nude mice as reported previously . When tumors reached 50 to 100 mm 3 , animals were dosed i.p. with 0.2 ml once daily. For Ras oncogene-transformed NIH3T3 cells, 2.5610 6 cells were implanted s.c. into each ank and drug treatments were initiated on day 3. Control animals received a saline vehicle whereas treated animals were injected with either FTI-276 or GGTI-297 or a combination of the two at the doses described in the FTI-276 and GGTI-297 antitumor activity and K-Ras prenylation J Sun et al legends. The tumor volumes were determined by measuring the length (l) and the width (w) and calculating the volume (V=lw 2 /2) as described previously .
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